Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) announced this morning that it has mutually agreed to terminate its combination with therapeutics company Intrinsic Medicine.
Similar to other SPACs, Phoenix Biotech disclosed that the two parties have decided to nix the deal due to the result of weakened markets. Chris Ehrlich, CEO and director of PBAX, noted in today’s press release, “After careful thought and consideration, we mutually determined that this action is in the best interest of all parties given current market conditions.”
Phoenix Biotech had just announced its $207 million business combination with Intrinsic Medicine on October 31. The therapeutics company expected to receive up to $178.8 million of cash held in trust through the deal.
PBAX, which originally had a timeline of 15 months, had a pending vote on December 16, to extend it’s deadline six months to July 8, 2023.
Terms Tracker for the Week Ending April 4, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This week may have been quiet for SPAC deal announcements, but the broader market was anything but. All eyes were on “Liberation Day,” as President...
Vickers Vantage II (NASDAQ:VCKBU) has gotten the band back together for a run at a SPAC deal with a $180 million vehicle after a nearly three-year break. The new SPAC is to have its trust slightly over-funded to 100.25% with $10.025 per unit in trust initially and those units are to each contain 1 right to...
YHN I (NASDAQ:YHNA) has entered into a definitive agreement to combine with Mingde Technology for $396 million in equity consideration. Transaction Overview YHN I has an estimated $61.6 million in its current trust, having IPO’d in September 2024. It has until December 20, 2025 to complete a deal under its current deadline. The two sides...
At the SPAC of Dawn While the markets digest the impact of the US’ new broad-based tariffs on the rest of the world, SPACs are making their first moves in the new landscape. As SPACInsider previewed in a post yesterday, Hennessy VI (NASDAQ:HCVI) was set to be the first shoe to drop as it had...
The tariffs have landed, and they appear set to define market conditions for the foreseeable future for ongoing SPAC target searches, but even more so for SPACs that have already announced a deal. The trade war comes at an awkward time for SPACs as 60% of pending business combinations – 55 of 91 – are...